Raul R Gainetdinov

List of Publications by Year in Descending Order

300 papers	29,694 citations	83 h-index	169 g-index
338 ext. papers	33,119 ext. citations	7.3 avg, IF	7.07 L-index

#	Paper	IF	Citations
300	Sexual dimorphism in COVID-19: potential clinical and public health implications.. *Lancet Diabetes and Endocrinology,the*, **2022**,	18.1	9
299	Trace amine-associated receptors at the cross-road between innate olfaction of amines, emotions, and adult neurogenesis. *Neural Regeneration Research*, **2022**, 17, 1257-1258	4.5	3
298	Modulation of Spatial Memory Deficit and Hyperactivity in Dopamine Transporter Knockout Rats 2A-Adrenoceptors.. *Frontiers in Psychiatry*, **2022**, 13, 851296	5	1
297	Trace Amine-Associated Receptor 2 Is Expressed in the Limbic Brain Areas and Is Involved in Dopamine Regulation and Adult Neurogenesis.. *Frontiers in Behavioral Neuroscience*, **2022**, 16, 847410	3.5	2
296	Evaluation of Approach to a Conspecific and Blood Biochemical Parameters in TAAR1 Knockout Mice. *Brain Sciences*, **2022**, 12, 614	3.4	1
295	Expression of Trace Amine-Associated Receptors in the Murine and Human Hippocampus Based on Public Transcriptomic Data. *Cells*, **2022**, 11, 1813	7.9	1
294	Trace Amine-Associated Receptors **2021**, 1498-1504		
293	Rare single nucleotide variants in COL5A1 promoter do not play a major role in keratoconus susceptibility associated with rs1536482. *BMC Ophthalmology*, **2021**, 21, 357	2.3	1
292	Disruption of the PDZ domain-binding motif of the dopamine transporter uniquely alters nanoscale distribution, dopamine homeostasis, and reward motivation. *Journal of Biological Chemistry*, **2021**, 297, 101361	5.4	1
291	Genetic Deletion of Trace-Amine Associated Receptor 9 (TAAR9) in Rats Leads to Decreased Blood Cholesterol Levels. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
290	A New Paradigm for Training Hyperactive Dopamine Transporter Knockout Rats: Influence of Novel Stimuli on Object Recognition. *Frontiers in Behavioral Neuroscience*, **2021**, 15, 654469	3.5	2
289	Divergent Dimethylarginine Dimethylaminohydrolase Isoenzyme Expression in the Central Nervous System. *Cellular and Molecular Neurobiology*, **2021**, 1	4.6	1
288	Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?. *Molecular Psychiatry*, **2021**,	15.1	15
287	Viral infiltration of pancreatic islets in patients with COVID-19. *Nature Communications*, **2021**, 12, 3534	17.4	34
286	Novel medium-sized di(het)areno-fused 1,4,7-(oxa)thiadiazecines as probes for aminergic receptors. *Mendeleev Communications*, **2021**, 31, 501-503	1.9	0
285	Effects of acute and chronic arecoline in adult zebrafish: Anxiolytic-like activity, elevated brain monoamines and the potential role of microglia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2021**, 104, 109977	5.5	15
284	A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2021**, 105, 110134	5.5	2

283	Increased dopamine transmission and adult neurogenesis in trace amine-associated receptor 5 (TAAR5) knockout mice. *Neuropharmacology*, **2021**, 182, 108373	5.5	19
282	Ouabain-Induced Gene Expression Changes in Human iPSC-Derived Neuron Culture Expressing Dopamine and cAMP-Regulated Phosphoprotein 32 and GABA Receptors. *Brain Sciences*, **2021**, 11,	3.4	2
281	Early Adolescence Prefrontal Cortex Alterations in Female Rats Lacking Dopamine Transporter. *Biomedicines*, **2021**, 9,	4.8	3
280	Minor Changes in Erythrocyte Osmotic Fragility in Trace Amine-Associated Receptor 5 (TAAR5) Knockout Mice. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
279	Rare cis-configured 2,4-disubstituted 1-alkylpiperidines: synthesized and tested against trace-amine-associated receptor 1 (TAAR1). *Mendeleev Communications*, **2021**, 31, 488-489	1.9	2
278	Pattern of TAAR5 Expression in the Human Brain Based on Transcriptome Datasets Analysis. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
277	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. *British Journal of Pharmacology*, **2021**, 178 Suppl 1, S27-S156	8.6	46
276	TAARs and Neurodegenerative and Psychiatric Disorders **2021**, 1-18		
275	Search for Structural Basis of Interactions of Biogenic Amines with Human TAAR1 and TAAR6 Receptors.. *International Journal of Molecular Sciences*, **2021**, 23,	6.3	2
274	Linking Ethanol-Addictive Behaviors With Brain Catecholamines: Release Pattern Matters.. *Frontiers in Behavioral Neuroscience*, **2021**, 15, 795030	3.5	0
273	Altered Sexual Behavior in Dopamine Transporter (DAT) Knockout Male Rats: A Behavioral, Neurochemical and Intracerebral Microdialysis Study. *Frontiers in Behavioral Neuroscience*, **2020**, 14, 58	3.5	14
272	Rats Lacking Dopamine Transporter Display Increased Vulnerability and Aberrant Autonomic Response to Acute Stress. *Biomolecules*, **2020**, 10,	5.9	3
271	Trace Amine-Associated Receptor 5 Provides Olfactory Input Into Limbic Brain Areas and Modulates Emotional Behaviors and Serotonin Transmission. *Frontiers in Molecular Neuroscience*, **2020**, 13, 18	6.1	30
270	The zebrafish tail immobilization (ZTI) test as a new tool to assess stress-related behavior and a potential screen for drugs affecting despair-like states. *Journal of Neuroscience Methods*, **2020**, 337, 108637	3	18
269	Cell Replacement Therapy in Parkinson's Disease—History of Development and Prospects for Use in Clinical Practice. *Molecular Biology*, **2020**, 54, 827-839	1.2	1
268	CRISPR/Cas9 Technology in Translational Biomedicine. *Cellular Physiology and Biochemistry*, **2020**, 54, 354-370	3.9	12
267	Deficit in working memory and abnormal behavioral tactics in dopamine transporter knockout rats during training in the 8-arm maze. *Behavioural Brain Research*, **2020**, 390, 112642	3.4	6
266	The Action of TAAR1 Agonist RO5263397 on Executive Functions in Rats. *Cellular and Molecular Neurobiology*, **2020**, 40, 215-228	4.6	5

265	Current challenges and possible future developments in personalized psychiatry with an emphasis on psychotic disorders. *Heliyon*, **2020**, 6, e03990	3.6	4
264	P.059 Identifying the role of trace amine-associated receptor 9 in behaviour, brain neurochemistry and blood biochemistry. *European Neuropsychopharmacology*, **2020**, 40, S39-S40	1.2	
263	P.062 Dopamine reuptake deficiency does not affect motor long-term motor memory in dopamine transporter-knockout rats. *European Neuropsychopharmacology*, **2020**, 40, S41	1.2	
262	Understanding complex dynamics of behavioral, neurochemical and transcriptomic changes induced by prolonged chronic unpredictable stress in zebrafish. *Scientific Reports*, **2020**, 10, 19981	4.9	7
261	Novel 1-Amidino-4-Phenylpiperazines as Potent Agonists at Human TAAR1 Receptor: Rational Design, Synthesis, Biological Evaluation and Molecular Docking Studies. *Pharmaceuticals*, **2020**, 13,	5.2	8
260	Enhanced Dopamine Transmission and Hyperactivity in the Dopamine Transporter Heterozygous Mice Lacking the D3 Dopamine Receptor. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
259	A low-cost and customizable alternative for commercial implantable cannula for intracerebral administration in mice.. *HardwareX*, **2020**, 8, e00120	2.7	
258	Minimal Age-Related Alterations in Behavioral and Hematological Parameters in Trace Amine-Associated Receptor 1 (TAAR1) Knockout Mice. *Cellular and Molecular Neurobiology*, **2020**, 40, 273-282	4.6	4
257	Putative Trace-Amine□Associated Receptor 5 (TAAR5) Agonist □NETA Increases Electrocorticogram Gamma-Rhythm in Freely Moving Rats. *Cellular and Molecular Neurobiology*, **2020**, 40, 203-213	4.6	9
256	Effect of alpha-NETA on auditory event related potentials in sensory gating study paradigm in mice. *Neuroscience Letters*, **2019**, 712, 134470	3.3	3
255	Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium. *Molecular Psychiatry*, **2019**, 24, 1099-1111	15.1	7
254	Trace Amine-Associated Receptor 1 Agonist Modulates Mismatch Negativity-Like Responses in Mice. *Frontiers in Pharmacology*, **2019**, 10, 470	5.6	8
253	The TAAR5 agonist □NETA causes dyskinesia in mice. *Neuroscience Letters*, **2019**, 704, 208-211	3.3	4
252	Effects of dopamine level on object recognition and formation of cognitive maps in rats. *European Neuropsychopharmacology*, **2019**, 29, S139-S140	1.2	1
251	Intracerebroventricular injection of ouabain causes mania-like behavior in mice through D2 receptor activation. *Scientific Reports*, **2019**, 9, 15627	4.9	9
250	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. *British Journal of Pharmacology*, **2019**, 176 Suppl 1, S21-S141	8.6	391
249	Dopamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. *IUPHAR/BPS Guide To Pharmacology CITE*, **2019**, 2019,	1.7	5
248	[illegible] [illegible]**2019**,		2

247	Comparative analysis of the influence of a high-fat/high-carbohydrate diet on the level of anxiety and neuromotor and cognitive functions in Wistar and DAT-KO rats. *Physiological Reports*, **2019**, 7, e13987	2.6	6
246	Identification of a novel trace amine-associated receptor 1 agonist with in vivo activity. *European Neuropsychopharmacology*, **2019**, 29, S190	1.2	2
245	Effect of trace amine-associated receptor 1 agonist RO5263397 on sensory gating in mice. *NeuroReport*, **2019**, 30, 1004-1007	1.7	4
244	P.112 Impaired conditioning in dopamine transporter knockout rats. *European Neuropsychopharmacology*, **2019**, 29, S94-S95	1.2	
243	In vivo voltammetric evidence that locus coeruleus activation predominantly releases norepinephrine in the infralimbic cortex: Effect of acute ethanol. *Synapse*, **2019**, 73, e22080	2.4	6
242	Behavioral characterization of DAT-KO rats and evidence of asocial-like phenotypes in DAT-HET rats: The potential involvement of norepinephrine system. *Behavioural Brain Research*, **2019**, 359, 516-527	3.4	18
241	Activation of trace amine-associated receptor 1 attenuates schedule-induced polydipsia in rats. *Neuropharmacology*, **2019**, 144, 184-192	5.5	6
240	Real-Time Accumbal Dopamine Response to Negative Stimuli: Effects of Ethanol. *ACS Chemical Neuroscience*, **2019**, 10, 1986-1991	5.7	5
239	Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models. *European Journal of Pharmacology*, **2018**, 829, 129-140	5.3	5
238	Novelty-related behavior of young and adult dopamine transporter knockout rats: Implication for cognitive and emotional phenotypic patterns. *Genes, Brain and Behavior*, **2018**, 17, e12463	3.6	19
237	Pronounced Hyperactivity, Cognitive Dysfunctions, and BDNF Dysregulation in Dopamine Transporter Knock-out Rats. *Journal of Neuroscience*, **2018**, 38, 1959-1972	6.6	82
236	Rational design, chemical synthesis and biological evaluation of novel biguanides exploring species-specificity responsiveness of TAAR1 agonists. *European Journal of Medicinal Chemistry*, **2018**, 146, 171-184	6.8	20
235	TAAR5 receptor agonist affects sensory gating in rats. *Neuroscience Letters*, **2018**, 666, 144-147	3.3	11
234	Human Accelerated Regions and Other Human-Specific Sequence Variations in the Context of Evolution and Their Relevance for Brain Development. *Genome Biology and Evolution*, **2018**, 10, 166-188	3.9	31
233	Identification of TAAR5 Agonist Activity of Alpha-NETA and Its Effect on Mismatch Negativity Amplitude in Awake Rats. *Neurotoxicity Research*, **2018**, 34, 442-451	4.3	12
232	No tolerance to anticompulsive activity of trace amine-associated receptor 1 agonist following repeated administration. *European Neuropsychopharmacology*, **2018**, 28, S38-S39	1.2	1
231	Interplay between the key proteins of serotonin system in SSRI antidepressants efficacy. *Expert Opinion on Therapeutic Targets*, **2018**, 22, 319-330	6.4	21
230	Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons. *Molecular Neurobiology*, **2018**, 55, 1054-1067	6.2	20

229	Dopamine D Receptor Supersensitivity as a Spectrum of Neurotoxicity and Status in Psychiatric Disorders. *Journal of Pharmacology and Experimental Therapeutics*, **2018**, 366, 519-526	4.7	12
228	Trace Amine-Associated Receptor 1 Modulates the Locomotor and Sensitization Effects of Nicotine. *Frontiers in Pharmacology*, **2018**, 9, 329	5.6	19
227	Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397. *Frontiers in Pharmacology*, **2018**, 9, 645	5.6	12
226	Behavioral Phenotyping of Dopamine Transporter Knockout Rats: Compulsive Traits, Motor Stereotypies, and Anhedonia. *Frontiers in Psychiatry*, **2018**, 9, 43	5	49
225	The Effects of Chronic Amitriptyline on Zebrafish Behavior and Monoamine Neurochemistry. *Neurochemical Research*, **2018**, 43, 1191-1199	4.6	33
224	Behavioral Effects of a Potential Novel TAAR1 Antagonist. *Frontiers in Pharmacology*, **2018**, 9, 953	5.6	4
223	Novel translational rat models of dopamine transporter deficiency. *Neural Regeneration Research*, **2018**, 13, 2091-2093	4.5	7
222	Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. *Expert Opinion on Therapeutic Targets*, **2018**, 22, 513-526	6.4	32
221	Trace Amines and Their Receptors. *Pharmacological Reviews*, **2018**, 70, 549-620	22.5	135
220	Recombinant Adeno-Associated Virus-mediated rescue of function in a mouse model of Dopamine Transporter Deficiency Syndrome. *Scientific Reports*, **2017**, 7, 46280	4.9	10
219	No effect of C1473G polymorphism in the tryptophan hydroxylase 2 gene on the response of the brain serotonin system to chronic fluoxetine treatment in mice. *Neuroscience Letters*, **2017**, 653, 264-268	3.3	7
218	Psychedelic Drugs in Biomedicine. *Trends in Pharmacological Sciences*, **2017**, 38, 992-1005	13.2	75
217	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. *British Journal of Pharmacology*, **2017**, 174 Suppl 1, S1-S16	8.6	231
216	Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges. *Pharmacology & Therapeutics*, **2017**, 180, 161-180	13.9	103
215	Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies. *European Journal of Medicinal Chemistry*, **2017**, 127, 781-792	6.8	24
214	A Caenorhabditis elegans model to study dopamine transporter deficiency syndrome. *European Journal of Neuroscience*, **2017**, 45, 207-214	3.5	8
213	The after-hours circadian mutant has reduced phenotypic plasticity in behaviors at multiple timescales and in sleep homeostasis. *Scientific Reports*, **2017**, 7, 17765	4.9	5
212	Optogenetically-induced tonic dopamine release from VTA-nucleus accumbens projections inhibits reward consummatory behaviors. *Neuroscience*, **2016**, 333, 54-64	3.9	38

211	Cross-hemispheric dopamine projections have functional significance. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 6985-90	11.5	48
210	Dopamine transporter mutant animals: a translational perspective. *Journal of Neurogenetics*, **2016**, 30, 5-15	1.6	33
209	Increased context-dependent conditioning to amphetamine in mice lacking TAAR1. *Pharmacological Research*, **2016**, 103, 206-14	10.2	23
208	A homology modelling-driven study leading to the discovery of the first mouse trace amine-associated receptor 5 (TAAR5) antagonists. *MedChemComm*, **2016**, 7, 353-364	5	25
207	Dimensions of GSK3 Monoamine-Related Intracellular Signaling in Schizophrenia. *Handbook of Behavioral Neuroscience*, **2016**, 23, 447-462	0.7	
206	Differences in effects of NMDA receptor antagonists in BARR2-KO mice. *European Neuropsychopharmacology*, **2016**, 26, S276	1.2	
205	Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy. *Science Translational Medicine*, **2016**, 8, 370ra181	17.5	22
204	Peripheral immunization of mice to produce antibodies against NMDA receptor as a potential approach to create a rodent model of schizophrenia. *European Neuropsychopharmacology*, **2016**, 26, S271-S272	1.2	
203	Understanding autism and other neurodevelopmental disorders through experimental translational neurobehavioral models. *Neuroscience and Biobehavioral Reviews*, **2016**, 65, 292-312	9	43
202	Genetic and environmental modulation of neurodevelopmental disorders: Translational insights from labs to beds. *Brain Research Bulletin*, **2016**, 125, 79-91	3.9	33
201	G protein-coupled receptor kinases as regulators of dopamine receptor functions. *Pharmacological Research*, **2016**, 111, 1-16	10.2	74
200	Hit-to-Lead Optimization of Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists with a Diphenylmethane-Scaffold: Design, Synthesis, and Biological Study. *Journal of Medicinal Chemistry*, **2016**, 59, 9825-9836	8.3	17
199	Regulation of Dopamine-Dependent Behaviors by G Protein-Coupled Receptor Kinases. *Methods in Pharmacology and Toxicology*, **2016**, 237-269	1.1	1
198	Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1. *Neuropharmacology*, **2015**, 93, 308-13	5.5	66
197	In-vivo pharmacology of Trace-Amine Associated Receptor 1. *European Journal of Pharmacology*, **2015**, 763, 136-42	5.3	25
196	Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E2517-26	11.5	73
195	TAAR1 Modulates Cortical Glutamate NMDA Receptor Function. *Neuropsychopharmacology*, **2015**, 40, 2217-27	8.7	74
194	Rapid Conversion of Fibroblasts into Functional Forebrain GABAergic Interneurons by Direct Genetic Reprogramming. *Cell Stem Cell*, **2015**, 17, 719-734	18	111

193	Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. *Neurobiology of Disease*, **2015**, 74, 66-75	7.5	91
192	The Concise Guide to PHARMACOLOGY 2015/16: Overview. *British Journal of Pharmacology*, **2015**, 172, 5729-43	8.6	207
191	The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels. *British Journal of Pharmacology*, **2015**, 172, 5870-903	8.6	128
190	The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. *British Journal of Pharmacology*, **2015**, 172, 5956-78	8.6	114
189	The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. *British Journal of Pharmacology*, **2015**, 172, 6024-109	8.6	515
188	The Concise Guide to PHARMACOLOGY 2015/16: Transporters. *British Journal of Pharmacology*, **2015**, 172, 6110-202	8.6	180
187	The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. *British Journal of Pharmacology*, **2015**, 172, 5744-869	8.6	475
186	The trace amine-associated receptor 1 modulates methamphetamine's neurochemical and behavioral effects. *Frontiers in Neuroscience*, **2015**, 9, 39	5.1	49
185	Design, Synthesis, and Evaluation of Thyronamine Analogues as Novel Potent Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists. *Journal of Medicinal Chemistry*, **2015**, 58, 5096-107	8.3	31
184	The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels. *British Journal of Pharmacology*, **2015**, 172, 5904-41	8.6	164
183	The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. *British Journal of Pharmacology*, **2015**, 172, 5979-6023	8.6	151
182	The Concise Guide to PHARMACOLOGY 2015/16: Other ion channels. *British Journal of Pharmacology*, **2015**, 172, 5942-55	8.6	38
181	Dopamine receptors - IUPHAR Review 13. *British Journal of Pharmacology*, **2015**, 172, 1-23	8.6	283
180	Dopamine D2 receptor relies upon PPM/PP2C protein phosphatases to dephosphorylate huntingtin protein. *Journal of Biological Chemistry*, **2014**, 289, 11715-11724	5.4	15
179	The electroretinogram as a biomarker of central dopamine and serotonin: potential relevance to psychiatric disorders. *Biological Psychiatry*, **2014**, 75, 479-86	7.9	64
178	Further insights into the pharmacology of the human trace amine-associated receptors: discovery of novel ligands for TAAR1 by a virtual screening approach. *Chemical Biology and Drug Design*, **2014**, 84, 712-20	2.9	32
177	Selective deletion of GRK2 alters psychostimulant-induced behaviors and dopamine neurotransmission. *Neuropsychopharmacology*, **2014**, 39, 2450-62	8.7	18
176	Activation of the trace amine-associated receptor 1 prevents relapse to cocaine seeking. *Neuropsychopharmacology*, **2014**, 39, 2299-308	8.7	61

175	In vivo amphetamine action is contingent on CaMKII. *Neuropsychopharmacology*, **2014**, 39, 2681-93	8.7	37
174	Exogenous Synuclein decreases raft partitioning of Cav2.2 channels inducing dopamine release. *Journal of Neuroscience*, **2014**, 34, 10603-15	6.6	41
173	Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors. *Neuropharmacology*, **2014**, 81, 283-91	5.5	98
172	TAAR1-dependent effects of apomorphine in mice. *International Journal of Neuropsychopharmacology*, **2014**, 17, 1683-93	5.8	30
171	Sustained N-methyl-d-aspartate receptor hypofunction remodels the dopamine system and impairs phasic signaling. *European Journal of Neuroscience*, **2014**, 40, 2255-63	3.5	9
170	Neuronal Functions and Emerging Pharmacology of TAAR1. *Topics in Medicinal Chemistry*, **2014**, 175-194	0.4	6
169	The dopamine transporter expression level differentially affects responses to cocaine and amphetamine. *Journal of Neurogenetics*, **2014**, 28, 112-21	1.6	16
168	Remote control of induced dopaminergic neurons in parkinsonian rats. *Journal of Clinical Investigation*, **2014**, 124, 3215-29	15.9	88
167	Trace Amines and Their Receptors: New Opportunities for Modulation of Brain Dopaminergic Functions **2014**, 92-93		
166	Transgenic mouse models for ADHD. *Cell and Tissue Research*, **2013**, 354, 259-71	4.2	47
165	Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice. *ACS Chemical Neuroscience*, **2013**, 4, 84-8	5.7	32
164	Insights into the structure and pharmacology of the human trace amine-associated receptor 1 (hTAAR1): homology modelling and docking studies. *Chemical Biology and Drug Design*, **2013**, 81, 509-16	2.9	43
163	BRET approaches to characterize dopamine and TAAR1 receptor pharmacology and signaling. *Methods in Molecular Biology*, **2013**, 964, 107-22	1.4	10
162	Rapid generation of functional dopaminergic neurons from human induced pluripotent stem cells through a single-step procedure using cell lineage transcription factors. *Stem Cells Translational Medicine*, **2013**, 2, 473-9	6.9	70
161	D1 dopamine receptor coupling to PLC regulates forward locomotion in mice. *Journal of Neuroscience*, **2013**, 33, 18125-33	6.6	38
160	Long-term optical stimulation of channelrhodopsin-expressing neurons to study network plasticity. *Frontiers in Molecular Neuroscience*, **2013**, 6, 22	6.1	29
159	The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatment. *Scientific Reports*, **2012**, 2, 301	4.9	19
158	Gene-dose dependent effects of methamphetamine on interval timing in dopamine-transporter knockout mice. *Neuropharmacology*, **2012**, 62, 1221-9	5.5	59

157	Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. *Biological Psychiatry*, **2012**, 72, 934-42	7.9	115
156	BRET biosensors to study GPCR biology, pharmacology, and signal transduction. *Frontiers in Endocrinology*, **2012**, 3, 105	5.7	65
155	Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment. *CNS and Neurological Disorders - Drug Targets*, **2012**, 11, 251-63	2.6	15
154	Rod vision is controlled by dopamine-dependent sensitization of rod bipolar cells by GABA. *Neuron*, **2011**, 72, 101-10	13.9	81
153	Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors. *Frontiers in Molecular Neuroscience*, **2011**, 4, 38	6.1	101
152	A functional alternative splicing mutation in human tryptophan hydroxylase-2. *Molecular Psychiatry*, **2011**, 16, 1169-76	15.1	19
151	Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. *Molecular Pharmacology*, **2011**, 80, 416-25	4.3	125
150	The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacological Reviews*, **2011**, 63, 182-217	22.5	1668
149	Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. *Nature*, **2011**, 476, 224-7	50.4	784
148	TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 8485-90	11.5	225
147	Paracrine modulation of cholangiocyte serotonin synthesis orchestrates biliary remodeling in adults. *American Journal of Physiology - Renal Physiology*, **2011**, 300, G303-15	5.1	32
146	Elimination of the vesicular acetylcholine transporter in the striatum reveals regulation of behaviour by cholinergic-glutamatergic co-transmission. *PLoS Biology*, **2011**, 9, e1001194	9.7	74
145	The dopamine metabolite 3-methoxytyramine is a neuromodulator. *PLoS ONE*, **2010**, 5, e13452	3.7	58
144	Noradrenergic control of cortico-striato-thalamic and mesolimbic cross-structural synchrony. *Journal of Neuroscience*, **2010**, 30, 6387-97	6.6	30
143	Tryptophan hydroxylase 2 genotype determines brain serotonin synthesis but not tissue content in C57Bl/6 and BALB/c congenic mice. *Neuroscience Letters*, **2010**, 481, 6-11	3.3	40
142	Strengths and limitations of genetic models of ADHD. *ADHD Attention Deficit and Hyperactivity Disorders*, **2010**, 2, 21-30	3.1	19
141	Hyperdopaminergic tone erodes prefrontal long-term potential via a D2 receptor-operated protein phosphatase gate. *Journal of Neuroscience*, **2009**, 29, 14086-99	6.6	49
140	Hyperdopaminergia and NMDA receptor hypofunction disrupt neural phase signaling. *Journal of Neuroscience*, **2009**, 29, 8215-24	6.6	75

139	Reduced D2-mediated signaling activity and trans-synaptic upregulation of D1 and D2 dopamine receptors in mice overexpressing the dopamine transporter. *Cellular Signalling*, **2009**, 21, 87-94	4.9	29
138	Reduced expression of the vesicular acetylcholine transporter causes learning deficits in mice. *Genes, Brain and Behavior*, **2009**, 8, 23-35	3.6	46
137	Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6. *Drug and Alcohol Dependence*, **2009**, 104, 187-96	4.9	31
136	Akt/GSK3 signaling in the action of psychotropic drugs. *Annual Review of Pharmacology and Toxicology*, **2009**, 49, 327-47	17.9	439
135	Trace amine-associated receptors as emerging therapeutic targets. *Molecular Pharmacology*, **2009**, 76, 229-35	4.3	77
134	Persistent hyperdopaminergia decreases the peak frequency of hippocampal theta oscillations during quiet waking and REM sleep. *PLoS ONE*, **2009**, 4, e5238	3.7	14
133	Role of Dopamine Transporters in Neuronal Homeostasis **2009**, 88-99		2
132	Food reward in the absence of taste receptor signaling. *Neuron*, **2008**, 57, 930-41	13.9	314
131	Trace amine associated receptor 1 and movement control. *Parkinsonism and Related Disorders*, **2008** , 14 Suppl 2, S99-102	3.6	40
130	A beta-arrestin 2 signaling complex mediates lithium action on behavior. *Cell*, **2008**, 132, 125-36	56.2	286
129	Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 4405-10	11.5	139
128	Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. *Brain*, **2008**, 131, 3361-79	11.2	28
127	Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 1333-8	11.5	292
126	A regulatory domain in the N terminus of tryptophan hydroxylase 2 controls enzyme expression. *Journal of Biological Chemistry*, **2008**, 283, 13216-24	5.4	27
125	Reply to Belmaker et al.: GSK3haploinsufficiency results in lithium-like effects in the forced-swim test. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, E24-E24	11.5	3
124	Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 13656-61	11.5	261
123	Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. *Molecular Pharmacology*, **2008**, 74, 585-594	4.3	104
122	Genetic NMDA receptor deficiency disrupts acute and chronic effects of cocaine but not amphetamine. *Neuropsychopharmacology*, **2008**, 33, 2701-14	8.7	40

121	Multibubble sonoluminescence of europium(III) chloride in heavy water. *Russian Chemical Bulletin*, **2008**, 57, 1827-1830	1.7	4
120	Effect of argon on the multibubble sonoluminescence of cerium, terbium, and dysprosium trichlorides. *Russian Chemical Bulletin*, **2008**, 57, 1831-1836	1.7	6
119	Dopamine transporter mutant mice in experimental neuropharmacology. *Naunyn-Schmiedebergls Archives of Pharmacology*, **2008**, 377, 301-13	3.4	62
118	Local knockdown of genes in the brain using small interfering RNA: a phenotypic comparison with knockout animals. *Biological Psychiatry*, **2007**, 61, 65-9	7.9	67
117	Dopamine levels modulate the updating of tastant values. *Genes, Brain and Behavior*, **2007**, 6, 314-20	3.6	36
116	Physiological roles of G protein-coupled receptor kinases and arrestins. *Annual Review of Physiology* , **2007**, 69, 511-34	23.1	391
115	Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. *Journal of Neuroscience*, **2007** , 27, 881-5	6.6	217
114	Mesolimbic dopamine in obesity and diabetes. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2007**, 293, R601-2	3.2	9
113	The Akt-GSK-3 signaling cascade in the actions of dopamine. *Trends in Pharmacological Sciences*, **2007**, 28, 166-72	13.2	325
112	Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2. *Cellular and Molecular Life Sciences*, **2006**, 63, 6-11	10.3	67
111	Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. *Journal of Biological Chemistry*, **2006**, 281, 32072-80	5.4	86
110	Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. *FASEB Journal*, **2006**, 20, 2541-3	0.9	52
109	Social context-dependent singing-regulated dopamine. *Journal of Neuroscience*, **2006**, 26, 9010-4	6.6	151
108	S.28.02 Influence of variants of TPH2 on the regulation of the central serotonin system. *European Neuropsychopharmacology*, **2006**, 16, S203-S204	1.2	
107	Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. *Neuron*, **2006**, 52, 359-69	13.9	232
106	Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. *Neuron*, **2006**, 51, 601-12	13.9	186
105	Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. *CNS and Neurological Disorders - Drug Targets*, **2006**, 5, 45-56	2.6	55
104	Chapter 5.1 Microdialysis in genetically altered animals. *Handbook of Behavioral Neuroscience*, **2006**, 399-417		

103	Anomalous isotopic effect in multibubble sonoluminescence of aqueous solutions of terbium chloride. *JETP Letters*, **2006**, 83, 493-496	1.2	5
102	Dopaminergic control of sleep-wake states. *Journal of Neuroscience*, **2006**, 26, 10577-89	6.6	213
101	Quenching of electronically excited Ln3+* ions by C60 fullerene. *Russian Chemical Bulletin*, **2006**, 55, 955-960	1.7	3
100	Sonoluminescence of terbium chloride in an H2O-D2O mixture. *Russian Chemical Bulletin*, **2006**, 55, 1114-1118	1.7	4
99	Dopamine: from pharmacology to molecular biology and back. *Wiener Klinische Wochenschrift*, **2006** , 118, 565-8	2.3	1
98	DDD mice, a novel acute mouse model of Parkinson's disease. *Neurology*, **2006**, 67, S12-7	6.5	16
97	An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. *Cell*, **2005**, 122, 261-73	56.2	787
96	Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. *Neuron*, **2005**, 45, 11-6	13.9	365
95	Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45, 11-16. *Neuron*, **2005**, 48, 702-3; author reply 705-6	13.9	25
94	Response to Correspondence: Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression. *Neuron*, **2005**, 48, 705-706	13.9	19
93	Characterization of conditioned place preference to cocaine in congenic dopamine transporter knockout female mice. *Psychopharmacology*, **2005**, 180, 408-13	4.7	29
92	Sonoluminescence of aqueous solution of gadolinium chloride. *Russian Chemical Bulletin*, **2005**, 54, 1383-1386	1.7	1
91	On the emitters of sulfuric acid sonoluminescence. *Russian Chemical Bulletin*, **2005**, 54, 1793-1797	1.7	2
90	Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. *PLoS Biology*, **2005**, 3, e271	9.7	99
89	G protein-coupled receptor kinase regulates dopamine D3 receptor signaling by modulating the stability of a receptor-filamin-beta-arrestin complex. A case of autoreceptor regulation. *Journal of Biological Chemistry*, **2005**, 280, 12774-80	5.4	75
88	The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. *Neuropsychopharmacology*, **2004**, 29, 221-8	8.7	112
87	Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 5099-104	11.5	668
86	Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 7781-6	11.5	86

85	Desensitization of G protein-coupled receptors and neuronal functions. *Annual Review of Neuroscience*, **2004**, 27, 107-44	17	677
84	Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine. *Journal of Neurochemistry*, **2004**, 91, 362-73	6	65
83	G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice. *NeuroMolecular Medicine*, **2004**, 5, 41-50	4.6	30
82	Tryptophan hydroxylase-2 controls brain serotonin synthesis. *Science*, **2004**, 305, 217	33.3	497
81	MDMA "ecstasy" alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. *Psychopharmacology*, **2004**, 173, 310-7	4.7	31
80	Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. *Neuron*, **2004**, 41, 625-38	13.9	305
79	Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 8987-92	11.5	409
78	Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. *Journal of Neuroscience*, **2003**, 23, 10265-73	6.6	167
77	Sonoluminescence of aqueous solutions of sulfuric acid and sulfur dioxide. *Russian Chemical Bulletin*, **2003**, 52, 1966-1968	1.7	9
76	Sonoluminescence of aqueous solutions of lanthanide salts. *Russian Chemical Bulletin*, **2003**, 52, 1969-1973	1.7	18
75	Presynaptic dopaminergic function is largely unaltered in mesolimbic and mesostriatal terminals of adult rats that were prenatally exposed to cocaine. *Brain Research*, **2003**, 961, 63-72	3.7	32
74	Plasma membrane monoamine transporters: structure, regulation and function. *Nature Reviews Neuroscience*, **2003**, 4, 13-25	13.5	735
73	Monoamine transporters: from genes to behavior. *Annual Review of Pharmacology and Toxicology*, **2003**, 43, 261-84	17.9	309
72	Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. *Neuron*, **2003**, 38, 291-303	13.9	194
71	Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 11035-40	11.5	119
70	Genetically Altered Mice as Models for Understanding Brain Disorders. *Research and Perspectives in Neurosciences*, **2003**, 65-84		
69	Dopaminergic transmission in the rat striatum in vivo in conditions of pharmacological modulation. *Neuroscience and Behavioral Physiology*, **2002**, 32, 183-8	0.3	12
68	Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. *Experimental Neurology*, **2002**, 175, 35-48	5.7	219

67	Experimental genetic approaches to addiction. *Neuron*, **2002**, 36, 213-28	13.9	71
66	Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. *Neuroscience*, **2002**, 112, 39-49	3.9	138
65	Monoamine transporter pharmacology and mutant mice. *Trends in Pharmacological Sciences*, **2002**, 23, 367-73	13.2	103
64	Following the trace of elusive amines. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 9474-5	11.5	128
63	Hyperactivity and impaired response habituation in hyperdopaminergic mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 1982-7	11.5	426
62	Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 11047-54	11.5	135
61	Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 15312-7	11.5	207
60	Dopamine transporter and vesicular monoamine transporter knockout mice : implications for Parkinson's disease. *Methods in Molecular Medicine*, **2001**, 62, 179-90		8
59	Effects of intrastriatal infusion of D2 and D3 dopamine receptor preferring antagonists on dopamine release in rat dorsal striatum (in vivo microdialysis study). *Pharmacological Research*, **2001**, 43, 283-90	10.2	14
58	Genetic animal models: focus on schizophrenia. *Trends in Neurosciences*, **2001**, 24, 527-33	13.3	178
57	Genetics of childhood disorders: XXIV. ADHD, part 8: hyperdopaminergic mice as an animal model of ADHD. *Journal of the American Academy of Child and Adolescent Psychiatry*, **2001**, 40, 380-2	7.2	60
56	Quantitation of in vivo measurements with carbon fiber microelectrodes. *Journal of Neuroscience Methods*, **2000**, 95, 95-102	3	70
55	Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. *Nature Neuroscience*, **2000**, 3, 465-71	25.5	383
54	Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. *Nature*, **2000**, 408, 720-3	50.4	709
53	An animal model of attention deficit hyperactivity disorder. *Trends in Molecular Medicine*, **2000**, 6, 43-4		63
52	Potentiated opioid analgesia in norepinephrine transporter knock-out mice. *Journal of Neuroscience* , **2000**, 20, 9040-5	6.6	97
51	Mice lacking the dopamine transporter display altered regulation of distal colonic motility. *American Journal of Physiology - Renal Physiology*, **2000**, 279, G311-8	5.1	55
50	Reply: receptor specificity of G-protein-coupled receptor kinases. *Trends in Pharmacological Sciences*, **2000**, 21, 366-7	13.2	24

49	Correlation between behavior and extracellular dopamine levels in rat striatum: comparison of microdialysis and fast-scan cyclic voltammetry. *Neuroscience Letters*, **2000**, 281, 9-12	3.3	80
48	Involvement of Dopamine Transporters in Psychiatric Disorders. *Neurobiological Foundation of Aberrant Behaviors*, **2000**, 1-18		
47	Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. *Journal of Neuroscience*, **1999**, 19, 2424-31	6.6	216
46	Delineating muscarinic receptor functions. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 12222-3	11.5	18
45	Loss of autoreceptor functions in mice lacking the dopamine transporter. *Nature Neuroscience*, **1999**, 2, 649-55	25.5	211
44	Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats. *Basic and Clinical Pharmacology and Toxicology*, **1999**, 85, 233-8		24
43	Application of microdialysis and voltammetry to assess dopamine functions in genetically altered mice: correlation with locomotor activity. *Psychopharmacology*, **1999**, 147, 30-2	4.7	22
42	Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. *European Journal of Pharmacology*, **1999**, 370, 125-31	5.3	36
41	Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. *Science*, **1999**, 283, 397-401	33.3	702
40	Enhanced morphine analgesia in mice lacking beta-arrestin 2. *Science*, **1999**, 286, 2495-8	33.3	815
39	Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice. *Neuron*, **1999**, 24, 1029-36	13.9	168
38	Dopamine turnover in the mediobasal hypothalamus in rat fetuses. *Neuroscience*, **1999**, 89, 235-41	3.9	30
37	Dopamine transporters and neuronal injury. *Trends in Pharmacological Sciences*, **1999**, 20, 424-9	13.2	276
36	Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. *Cell*, **1999**, 98, 427-36	56.2	882
35	Functional hyperdopaminergia in dopamine transporter knock-out mice. *Biological Psychiatry*, **1999**, 46, 303-11	7.9	180
34	Genetic approaches to studying norepinephrine function: knockout of the mouse norepinephrine transporter gene. *Biological Psychiatry*, **1999**, 46, 1124-30	7.9	64
33	Cocaine self-administration in dopamine-transporter knockout mice. *Nature Neuroscience*, **1998**, 1, 132-7	25.5	408
32	Effect of subchronic administration of tolcapone on L-DOPA-and carbidopa-induced release of striatal dopamine and its metabolites. *Bulletin of Experimental Biology and Medicine*, **1998**, 125, 145-147	0.8	1

31	Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. *Brain Research Reviews*, **1998**, 26, 148-53		200
30	Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. *Journal of Neurochemistry*, **1998**, 70, 1973-8	6	135
29	Profound neuronal plasticity in response to inactivation of the dopamine transporter. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 4029-34	11.5	547
28	Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. *Journal of Neuroscience*, **1998**, 18, 4861-9	6.6	218
27	Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. *Journal of Neuroscience*, **1998**, 18, 1979-86	6.6	478
26	Effects of a psychostimulant drug sydnocarb on rat brain dopaminergic transmission in vivo. *European Journal of Pharmacology*, **1997**, 340, 53-8	5.3	13
25	Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. *Neuron*, **1997**, 19, 127-38	13.9	176
24	Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. *Neuron*, **1997**, 19, 1285-96	13.9	302
23	Effect of the aspartic acid derivatives N-acetyl-aspartate and its phosphonic analog PIR-87-6-0 on the release of dopamine from rat striatum duringin vitro perfusion. *Bulletin of Experimental Biology and Medicine*, **1997**, 123, 49-51	0.8	
22	Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. *Journal of Neurochemistry*, **1997**, 69, 1322-5	6	258
21	Simultaneous monitoring of dopamine, its metabolites and trans-isomer of atypical neuroleptic drug carbidine concentrations in striatal dialysates of conscious rats. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **1996**, 20, 291-305	5.5	5
20	In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. *European Journal of Pharmacology*, **1996**, 308, 261-9	5.3	65
19	Dopamine autoreceptors of subtype D3 regulate mainly dopamine release in the basal ganglia of rat brain. *Bulletin of Experimental Biology and Medicine*, **1996**, 121, 392-396	0.8	
18	Substances increasing the extracellular content of dopamine in the striatum prevent the development of haloperidol catalepsy in rats. *Bulletin of Experimental Biology and Medicine*, **1996**, 121, 399-401	0.8	6
17	Regulation of dopamine release and metabolism in rat striatum in vivo: effects of dopamine receptor antagonists. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **1995**, 19, 1285-1303	5.5	21
16	Estimation of the interstitial free concentration of the putative dopamine D3 receptor selective agonist 7-OH-DPAT in the dorsal striatum of freely moving rats. *Neuroscience Letters*, **1995**, 193, 65-7	3.3	7
15	Preferential role of D3 dopamine autoreceptor in regulation of dopamine release but not synthesis in nucleus accumbens and dorsal striatum of freely moving rats. *Behavioural Pharmacology*, **1995**, 6, 74	2.4	152
14	Effect of bromantane, a new immunostimulating agent with psychostimulating activity, on the release and metabolism of dopamine in the striatum of freely moving rats. A microdialysis study. *Bulletin of Experimental Biology and Medicine*, **1995**, 119, 294-296	0.8	4

13	Dopamine D2 and D3 receptor preferring antagonists differentially affect striatal dopamine release and metabolism in conscious rats. *European Journal of Pharmacology*, **1994**, 261, 327-31	5.3	32
12	Remoxipride and raclopride differ from metoclopramide by their effects on striatal dopamine release and biosynthesis in rats. *Neuropharmacology*, **1994**, 33, 215-9	5.5	11
11	Use of sodium hydroxybutyrate and nooglutyl to correct dopamine release in the striatum of prenatally alcoholized rat pups. *Bulletin of Experimental Biology and Medicine*, **1993**, 116, 832-834	0.8	1
10	Age-related changes in the dopaminergic system of rat striatum. *Bulletin of Experimental Biology and Medicine*, **1993**, 115, 331-333	0.8	2
9	Effects of N-acetylaspartic acid on the brain after frontal lobectomy in rats: Antiamnestic effect and influence on monoamine content. *Bulletin of Experimental Biology and Medicine*, **1993**, 115, 155-158	0.8	3
8	Effect of haloperidol on extracellular concentrations of dopamine and its metabolites in the rat septum during muricidal aggression. *Bulletin of Experimental Biology and Medicine*, **1992**, 114, 1221-1223	0.8	0
7	Different effects of typical and atypical neuroleptics on K+-stimulated dopamine release from isolated rat striatum. *Bulletin of Experimental Biology and Medicine*, **1992**, 114, 971-974	0.8	1
6	Selective analyzers of D2-dopamine receptors modulate serotonin metabolism in the striatum and nucleus accumbens after dopaminergic neuron blockade. *Bulletin of Experimental Biology and Medicine*, **1992**, 113, 821-824	0.8	2
5	Comparison of neurochemical activity profiles of remoxipride, raclopride, and metoclopramide. *Bulletin of Experimental Biology and Medicine*, **1992**, 114, 1135-1139	0.8	
4	Microdialysis study of effects of atypical neuroleptics and anxiolytics on striatal dopamine release and metabolism in conscious rats. *Bulletin of Experimental Biology and Medicine*, **1991**, 111, 655-658	0.8	2
3	Action of small doses of irradiation on hypothalamic monoamine levels in hypoxic and normoxic rats. *Bulletin of Experimental Biology and Medicine*, **1991**, 112, 1508-1510	0.8	
2	Stereoisomers of the atypical neuroleptic carbidine modulate striatal dopamine release in awake rats. *Neuropharmacology*, **1991**, 30, 1251-4	5.5	8
1	Attention-deficit hyperactivity disorder164-172		